Journal of Capital Medical University ›› 2016, Vol. 37 ›› Issue (5): 568-573.doi: 10.3969/j.issn.1006-7795.2016.05.002

Previous Articles     Next Articles

Effects of dust mite allergy immunotherapy on clinical efficacy and airway hyperresponsiveness in allergic asthma and rhinitis children sensitized to dust mite

Huang Huijie, Liu Xiaoying, Hou Xiaoling, Miao Qing, Xiang Li   

  1. Department of Allergy, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China
  • Received:2016-06-30 Online:2016-10-21 Published:2016-10-19
  • Supported by:
    This study was supported by Capital Characteristic Clinical Application(Z151100004015030), Beijing Programs for Science and Technology(Z131100006813044).

Abstract: Objective To understand the clinical efficacy in children with asthma and allergic rhinitis who received the dust mite allergy immunotherapy(AIT), and to discuss the influence of dust mite allergy immunotherapy on airway hyperresponsiveness. Methods A total of 26 cases with mild or moderate persistent asthma complicated with allergic rhinitis who received the dust mite specific immunotherapy combined with drug therapy between February 2012 and November 2012 in Beijing Children's Hospital were enrolled in the case-self-control study. Results Totally 26 cases completed treatment for three years and monitoring airway hyperresponsiveness. The average daily Symptom and Medication Score (SMS) at one, two and three years after the dust mite allergy immunotherapy were 3.3±1.5, 2.2±1.6,1.1±1.3 respectively, which were significantly lower than at the baseline values (6.1±2.3) (P<0.05), ACT/C-ACT assessment at one, two and three years after AIT were 24.7±2.6, 25.0±1.5, 25.2±1.8 respectively, which were higher than that at the baseline (22.2±3.3) (P<0.05); Asthma Visual Analog Scale (VAS) at one, two and three years after AIT were 1.1±1.7, 1.1±1.03, 0.6±1.09 respectively, which were significantly lower than that at the baseline (2.8±2.5) (P<0.05). Allergic rhinitis VAS score at one and two and three year after AIT were 1.7±1.9, 1.9±1.7, 1.2±1.3 respectively, which were significantly lower than at the baseline (4.7±2.0) (P<0.05). However, the pulmonary function index was not significantly different after the treatment. Respiratory resistance (RrS) at two and three year after AIT were 7.461±2.464, 6.957±2.440, which were significantly lower than at one year(8.176±2.634)(P<0.05); Respiratory conductance (Grs) at two and three year after AIT were 0.151±0.062, 0.163±0.067, which were higher than that at one year (0.135±0.045) (P<0.05); Minimum dose of bronchoconstrictor or the amount of the cumulative dose at the inflection point where the reciprocal of Rrs (Grs) decreases linearly (Dmin) at two and three year after AIT were 9.558±9.487, 19.640±12.379, which were higher than that at one year (7.110±10.865) (P<0.05). Conclusion The dust mite allergy immunotherapy could improve symptoms significantly, reduced asthma controller medication, improved airway hyperresponsiveness but did not significantly improve the spirometric parameters.

Key words: asthma, allergic rhinitis, children, allergy immunotherapy, airway hyperresponsiveness

CLC Number: